Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype

Assessment of individual cardiovascular risk, distinguishing primary and secondary prevention, would improve the clinical management of the population with familial hypercholesterolemia. We aimed to develop and validate two risk functions to predict incident and recurrent atherosclerotic cardiovascu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 2020-01, Vol.292, p.42-51
Hauptverfasser: Ramos, Rafel, Masana, Luís, Comas-Cufí, Marc, García-Gil, Maria, Martí-Lluch, Ruth, Ponjoan, Anna, Plana, Núria, Alves-Cabratosa, Lia, Marrugat, Jaume, Elosua, Roberto, Dégano, Irene R., Gomez-Marcos, Mauel A., Zamora, Alberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Assessment of individual cardiovascular risk, distinguishing primary and secondary prevention, would improve the clinical management of the population with familial hypercholesterolemia. We aimed to develop and validate two risk functions to predict incident and recurrent atherosclerotic cardiovascular disease (ASCVD) in a primary care-based population with familial hypercholesterolemia phenotype (FHP), and to compare their predictive capacity with that of the SpAnish Familial hypErcHolEsterolemiA cohoRT (SAFEHEART) risk equation (SAFEHEART-RE). Data from the Catalan primary care system database (SIDIAP) of patients ≥18 years old with FHP in 2006–2013 were used to develop and validate two risk functions to predict incident and recurrent ASCVD. A validation dataset was also used to compare the model predictive capacity to that of SAFEHEART-RE. The new model (SIDIAP-FHP) included age, diabetes, smoking, sex (male), hypertension, and baseline low-density lipoprotein cholesterol in the primary prevention cohort and age, diabetes, smoking, and disease characteristics (progressive, recent, polyvascular, or included myocardial infarction) in the secondary prevention cohort. The models demonstrated a fair fit: C-Statistic: 0.71 (95%CI:0.68–0.75) in primary prevention and 0.65 (95%CI:0.60–0.70) in secondary prevention (higher than that of SAFEHEART-RE: 0.64 [95%CI:0.60–0.68] and 0.55 [95%CI:0.51–0.59], respectively; both p 
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2019.10.016